Investor Presentaiton

Investor presentation Full year 2018 Slide 73 Ambition for OzempicⓇ to become leading weekly GLP-1, with daily GLP-1 users shifting to oral semaglutide Promotional focus shifted from Victoza® towards OzempicⓇ as market access emerges Illustrative Aim for OzempicⓇ and oral semaglutide to replace VictozaⓇ as market leaders Illustrative Commercial focus changing diabetes VICTOZA liraglutide injection OZEMPİC semaglutide injection OzempicⓇ market access Prescription volume VICTOZAⓇ liraglutide injection OZEMPİC semaglutide injection Time 1 VictozaⓇ patent expiry expected in 2022/2023 in most markets oral semaglutide VictozaⓇ patent expiry¹ novo nordisk

View entire presentation